At BELLUS Health, we are working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough.

Our Company Content

It has been 6 decades since the last treatment was approved for cough in the U.S. and currently, there are no approved treatments available in the U.S. for patients suffering from refractory chronic cough. It is our mission to address this important need and deliver unique therapies that can improve the lives of patients living with cough. Our team of dedicated life science veterans and leading drug development experts is advancing the development of our selective P2X3 antagonist, camlipixant, which is currently being investigated in two Phase 3 trials. We are confident in camlipixant’s potential to be a breakthrough in the refractory chronic cough treatment landscape and provide patients the cough relief they are seeking.

IR Section

We invite you to visit our investor relations page, including our Annual Information Form, to obtain more information about BELLUS Health.